Neutrophil Extracellular Traps (NETs) Promote Pro-Metastatic Phenotype in Human Breast Cancer Cells through Epithelial-Mesenchymal Transition. 2020

Karina Martins-Cardoso, and Vitor H Almeida, and Kayo M Bagri, and Maria Isabel Doria Rossi, and Claudia S Mermelstein, and Sandra König, and Robson Q Monteiro
Institute of Medical Biochemistry Leopoldo de Meis, Federal University of Rio de Janeiro, Rio de Janeiro 21941 590, Brazil.

Neutrophil extracellular traps (NETs) have been associated with several steps of tumor progression, including primary growth and metastasis. One of the key features for the acquisition of the metastatic ability is the epithelial-mesenchymal transition (EMT), a complex cellular program. In this study, we evaluated the ability of isolated NETs in modulating the pro-metastatic phenotype of human breast cancer cells. Tumor cells were treated with isolated NETs and then samples were generated for cell migration, quantitative RT-PCR, western blotting, immunofluorescence, and flow cytometry assays. RNA-seq data from The Cancer Genome Atlas (TCGA) database were assessed. NETs changed the typical epithelial morphology of MCF7 cells into a mesenchymal phenotype, a process that was accompanied by enhanced migratory properties. Additional EMT traits were observed: increased expression of N-cadherin and fibronectin, while the E-cadherin expression was repressed. Notably, NETs positively regulated the gene expression of several factors linked to the pro-inflammatory and pro-metastatic properties. Analyses of TCGA data showed that samples from breast cancer patients exhibit a significant correlation between pro-tumoral and neutrophil signature gene expression, including several EMT and pro-metastatic factors. Therefore, NETs drive pro-metastatic phenotype in human breast cancer cells through the activation of the EMT program.

UI MeSH Term Description Entries

Related Publications

Karina Martins-Cardoso, and Vitor H Almeida, and Kayo M Bagri, and Maria Isabel Doria Rossi, and Claudia S Mermelstein, and Sandra König, and Robson Q Monteiro
July 2021, International journal of molecular medicine,
Karina Martins-Cardoso, and Vitor H Almeida, and Kayo M Bagri, and Maria Isabel Doria Rossi, and Claudia S Mermelstein, and Sandra König, and Robson Q Monteiro
April 2022, The Journal of pathology,
Karina Martins-Cardoso, and Vitor H Almeida, and Kayo M Bagri, and Maria Isabel Doria Rossi, and Claudia S Mermelstein, and Sandra König, and Robson Q Monteiro
April 2020, International journal of molecular sciences,
Karina Martins-Cardoso, and Vitor H Almeida, and Kayo M Bagri, and Maria Isabel Doria Rossi, and Claudia S Mermelstein, and Sandra König, and Robson Q Monteiro
December 2021, Cancers,
Karina Martins-Cardoso, and Vitor H Almeida, and Kayo M Bagri, and Maria Isabel Doria Rossi, and Claudia S Mermelstein, and Sandra König, and Robson Q Monteiro
September 2017, Oncotarget,
Karina Martins-Cardoso, and Vitor H Almeida, and Kayo M Bagri, and Maria Isabel Doria Rossi, and Claudia S Mermelstein, and Sandra König, and Robson Q Monteiro
July 2017, Arteriosclerosis, thrombosis, and vascular biology,
Karina Martins-Cardoso, and Vitor H Almeida, and Kayo M Bagri, and Maria Isabel Doria Rossi, and Claudia S Mermelstein, and Sandra König, and Robson Q Monteiro
August 2009, Oncogene,
Karina Martins-Cardoso, and Vitor H Almeida, and Kayo M Bagri, and Maria Isabel Doria Rossi, and Claudia S Mermelstein, and Sandra König, and Robson Q Monteiro
January 2021, International journal of medical sciences,
Karina Martins-Cardoso, and Vitor H Almeida, and Kayo M Bagri, and Maria Isabel Doria Rossi, and Claudia S Mermelstein, and Sandra König, and Robson Q Monteiro
September 2017, Scientific reports,
Karina Martins-Cardoso, and Vitor H Almeida, and Kayo M Bagri, and Maria Isabel Doria Rossi, and Claudia S Mermelstein, and Sandra König, and Robson Q Monteiro
June 2017, Journal of cellular physiology,
Copied contents to your clipboard!